Literature DB >> 8095616

Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis.

B Tjellström, L Stenhammar, S Eriksson, K E Magnusson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8095616     DOI： 10.1016/0140-6736(93)90477-x

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  20 in total

Review 1.  Passive immunity against human pathogens using bovine antibodies.

Authors:  C Weiner; Q Pan; M Hurtig; T Borén; E Bostwick; L Hammarström
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

Review 2.  Immune-based treatment and prevention of Clostridium difficile infection.

Authors:  Song Zhao; Chandrabali Ghose-Paul; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 3.  Recurrent Clostridium difficile infection: From colonization to cure.

Authors:  Kelsey Shields; Roger V Araujo-Castillo; Thimmaiah G Theethira; Carolyn D Alonso; Ciaran P Kelly
Journal:  Anaerobe       Date:  2015-04-27       Impact factor: 3.331

4.  Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine.

Authors:  M Warny; A Fatimi; E F Bostwick; D C Laine; F Lebel; J T LaMont; C Pothoulakis; C P Kelly
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

5.  Intravenous immunoglobulin therapy for severe Clostridium difficile colitis.

Authors:  J Salcedo; S Keates; C Pothoulakis; M Warny; I Castagliuolo; J T LaMont; C P Kelly
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

6.  Lack of effect of orally administered human serum immunoglobulin on the normal human oral and intestinal microflora.

Authors:  A K Bogstedt; C E Nord; L Hammarström
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-01       Impact factor: 3.267

7.  Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain.

Authors:  Greg Hussack; Mehdi Arbabi-Ghahroudi; Henk van Faassen; J Glenn Songer; Kenneth K-S Ng; Roger MacKenzie; Jamshid Tanha
Journal:  J Biol Chem       Date:  2011-01-07       Impact factor: 5.157

8.  A double-blind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder.

Authors:  Benjamin L Handen; Raun D Melmed; Robin L Hansen; Michael G Aman; David L Burnham; Jon B Bruss; Christopher J McDougle
Journal:  J Autism Dev Disord       Date:  2009-01-16

9.  Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins.

Authors:  C P Kelly; C Pothoulakis; F Vavva; I Castagliuolo; E F Bostwick; J C O'Keane; S Keates; J T LaMont
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

10.  Effects of spray-dried porcine plasma on fecal microbiota in nursery pigs.

Authors:  Huyen Tran; Christopher L Anderson; Justin W Bundy; Samodha C Fernando; Phillip S Miller; Thomas E Burkey
Journal:  J Anim Sci       Date:  2018-04-03       Impact factor: 3.159
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.